Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Current Investments (2016 - 2025)

Iovance Biotherapeutics has reported Cash & Current Investments over the past 12 years, most recently at $297.0 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $297.0 million for Q4 2025, down 8.28% from a year ago — trailing twelve months through Dec 2025 was $297.0 million (down 8.28% YoY), and the annual figure for FY2025 was $297.0 million, down 8.28%.
  • Cash & Current Investments for Q4 2025 was $297.0 million at Iovance Biotherapeutics, down from $300.8 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for IOVA hit a ceiling of $626.3 million in Q1 2023 and a floor of $164.2 million in Q3 2024.
  • Median Cash & Current Investments over the past 3 years was $301.0 million (2025), compared with a mean of $320.8 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 54.57% in 2024 and later skyrocketed 83.23% in 2025.
  • Iovance Biotherapeutics' Cash & Current Investments stood at $279.9 million in 2023, then increased by 15.69% to $323.8 million in 2024, then fell by 8.28% to $297.0 million in 2025.
  • The last three reported values for Cash & Current Investments were $297.0 million (Q4 2025), $300.8 million (Q3 2025), and $301.2 million (Q2 2025) per Business Quant data.